Volume Spike Investor

United Therapeutics (NASDAQ: UTHR) is down sharply this morning on news that the company’s pulmonary arterial hypertension product failed to meet its primary objectives.  The company did say this will merit ongoing studies and Eli Lilly (NYSE: LLY) has licensed the rights to UTHR for $150 million in an equity stake. UTHR is trading down [...]